日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.

使用 FLT PET/CT 对采用 X-82 和多西他赛序贯联合治疗的晚期实体恶性肿瘤进行药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-018-3599-3
Scarpelli Matthew, Rampurwala Murtuza, Eickhoff Jens, Carmichael Lakeesha, Heideman Jennifer, Binger Kimberly, Kolesar Jill, Perlman Scott, Harrow Kim, Dukart Gary, Liang Chris, Jeraj Robert, Liu Glenn, Bruce Justine Yang
肿瘤
肿瘤免疫
发表日期：2018
文献求助 收藏

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

一项评估替万替尼联合替西罗莫司治疗晚期实体瘤患者的I期临床研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-016-0418-8
Kyriakopoulos, Christos E; Braden, Amy M; Kolesar, Jill M; Eickhoff, Jens C; Bailey, Howard H; Heideman, Jennifer; Liu, Glenn; Wisinski, Kari B
发表日期：2017
文献求助 收藏

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials

细胞色素P-450药物相互作用在转移性实体瘤成人患者中的潜在影响及其对I期临床试验入组资格的影响

期刊:American Journal of Health-System Pharmacy
影响因子:2.3
doi:10.2146/ajhp140591
Wisinski, Kari B; Cantu, Colby A; Eickhoff, Jens; Osterby, Kurt; Tevaarwerk, Amye J; Heideman, Jennifer; Liu, Glenn; Wilding, George; Johnston, Susan; Kolesar, Jill M
细胞生物学
发表日期：2015
文献求助 收藏

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.

采用 (18)F-3'脱氧-3'氟-L-胸苷正电子发射断层扫描/计算机断层扫描评估阿昔替尼在晚期恶性肿瘤患者中的药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-015-2779-7
Bruce Justine Yang, Scully Peter Colin, Carmichael Lakeesha L, Eickhoff Jens C, Perlman Scott B, Kolesar Jill Marie, Heideman Jennifer L, Jeraj Robert, Liu Glenn
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

一项针对肾细胞癌和其他晚期实体恶性肿瘤患者的舒尼替尼联合贝伐单抗序贯治疗的I期药效学试验

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-013-2373-9
Bruce, Justine Yang; Kolesar, Jill M; Hammers, Hans; Stein, Mark N; Carmichael, Lakeesha; Eickhoff, Jens; Johnston, Susan A; Binger, Kimberly A; Heideman, Jennifer L; Perlman, Scott B; Jeraj, Robert; Liu, Glenn
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2014
文献求助 收藏